试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
编号:NCT02284737登记状态:提前终止企业 / 申办者:Nanjing First Hospital, Nanjing Medical University
药物 / 成分:PADN、sham PADN、Sildenafil
登记的停止原因(原文):Lack of subjects.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
编号:NCT03345784登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Adavosertib、Cisplatin、External Beam Radiation Therapy
登记的停止原因(原文):Inadequate accrual rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE
编号:NCT03355482登记状态:提前终止企业 / 申办者:Oklahoma Medical Research Foundation
药物 / 成分:Methylprednisolone、Placebos
登记的停止原因(原文):poor recruitment, funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
Pessary Versus Cerclage With or Without Progesterone in Twins
编号:NCT03863613登记状态:提前终止企业 / 申办者:Mỹ Đức Hospital
药物 / 成分:Pessary、Cervical cerclage、Vaginal progesterone
登记的停止原因(原文):Due to safety concerns as the PTB \<28 weeks and perinatal death rates were significantly higher in the pessary group, following the DSMC's recommendation.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
编号:NCT03950414登记状态:提前终止企业 / 申办者:University of Wisconsin, Madison
药物 / 成分:CMV specific T-cells
登记的停止原因(原文):Insufficient Patient Population
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
编号:NCT03997448登记状态:提前终止企业 / 申办者:Nataliya Uboha
药物 / 成分:Pembrolizumab、Abemaciclib
登记的停止原因(原文):Funder decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
COVID-19 Ozanimod Intervention Study
编号:NCT04405102登记状态:提前终止企业 / 申办者:Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
药物 / 成分:Ozanimod、Standard of care
登记的停止原因(原文):Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-20
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
编号:NCT05060003登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Atezolizumab、Tiragolumab、Signatera Assay
登记的停止原因(原文):Sponsor made decision to terminate study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
编号:NCT03239470登记状态:提前终止企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:Cohort 1: 1.0 x 10^8 PolyTregs、Cohort 2: 2.5x10^8 PolyTregs
登记的停止原因(原文):Lack of recruitment, ongoing and new feasibility issues, and the impact of the coronavirus infectious disease 19 (COVID-19) pandemic
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
编号:NCT03818776登记状态:提前终止企业 / 申办者:Case Comprehensive Cancer Center
药物 / 成分:Durvalumab、Proton beam therapy RT
登记的停止原因(原文):Safety
查看官方原始记录 ↗